A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability
Mathilde Moreau,Emily Alouani,Clémence Flecchia,Antoine Falcoz,Claire Gallois,Edouard Auclin,Thierry André,Romain Cohen,Antoine Hollebecque,Anthony Turpin,Simon Pernot,Thérèse Masson,Frederic Di Fiore,Marie Dutherge,Thibault Mazard,Vincent Hautefeuille,Jean-Luc Van Laethem,Christelle De la Fouchardière,Géraldine Perkins,Meher Ben-Abdelghani,Francesco Sclafani,Thomas Aparicio,Stefano Kim,Dewi Vernerey,Julien Taieb,Rosine Guimbaud,David Tougeron
DOI: https://doi.org/10.1016/j.ejca.2024.114033
IF: 10.002
2024-03-23
European Journal of Cancer
Abstract:Background One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced dMMR/MSI-H digestive tumors. Methods In this multicenter study, we included patients with advanced dMMR/MSI-H non-colorectal digestive tumors treated with chemotherapy and/or ICIs. Patients were divided retrospectively into two groups, a CT group and an IO group. The primary endpoint was progression-free survival (PFS). A propensity score approach using the inverse probability of treatment weighting (IPTW) method was applied to deal with potential differences between the two groups. Results 133 patients (45.1/27.1/27.8% with gastric/small bowel/other carcinomas) were included. The majority of patients received ICI in 1 st (29.1%) or 2 nd line (44.4%). The 24-month PFS rates were 7.9% in the CT group and 71.2% in the IO group. Using the IPTW method, IO treatment was associated with better PFS (HR=0.227; 95% CI 0.147-0.351; p<0.0001). The overall response rate was 26.3% in the CT group versus 60.7% in the IO group (p<0.001) with prolonged duration of disease control in the IO group (p<0.001). In multivariable analysis, predictive factors of PFS for patients treated with IO were good performance status, absence of liver metastasis and prior primary tumor resection, whereas no association was found for the site of the primary tumor. Conclusions In the absence of randomized trials, our study highlights the superior efficacy of ICI compared with standard-of-care therapy in patients with unresectable or metastatic dMMR/MSI-H non-colorectal digestive cancer, regardless of tumor type, with acceptable toxicity.
oncology